Develops, manufactures and sells enzymes across four segments. Human Healthcare contributes 63% of FY26 revenue (INR 745.8 crore) and is led by Serratiopeptidase, an anti-inflammatory enzyme that grew ~45% YoY and is awaiting EU novel-food approval expected in FY27. Animal Nutrition (13% of revenue) grew 25% YoY; Bioprocessing grew 16% and Specialized Manufacturing grew 23% YoY. Three subsidiaries — JC Biotech (INR 72.8 crore FY26 revenue), Scitech (INR 66.8 crore) and Evoxx (INR 31.9 crore, turned EBITDA positive) — extend the company into contract enzyme and specialised manufacturing. Exports reached 52 countries at 33.58% of standalone turnover, with the U.S. nutraceutical business absorbing an ~18% tariff headwind. A new R&D centre in Nashik with 3x current capacity (INR 130 crore total capex) is scheduled to go live in H2 FY27, alongside 2 EU EFSA and 3 US FDA dossiers under review. Largest cost items are materials (26.1% of revenue), employees (21.8%) and other operating expenses (21.6%), with management flagging input cost inflation from fuel, salt, solvents, packaging and logistics. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Human Healthcare (63%), Animal Nutrition (13%), Bioprocessing, Specialized Manufacturing. R&D-intensive, multi-segment enzyme manufacturer spanning human health, animal nutrition, bioprocessing and specialised manufacturing.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 529 | 541 | 624 | 637 | 746 |
| EBITDA (ex other income) | 201 | 152 | 189 | 194 | 240 |
| margin % | 38.0 | 28.2 | 30.3 | 30.5 | 32.2 |
| Owners' profit | 120 | 106 | 133 | 131 | 169 |
| EPS, as reported (₹) | 10.70 | 9.45 | 11.92 | 11.72 | 15.08 |
| ROE % · ROCE % | 10.9 · 14.3 | 8.1 · 10.6 | 10.0 · 13.3 | 9.1 · 12.5 | 10.3 · 13.6 |
| Debt / equity (x) | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 |
| Cash from operations | 124 | 140 | 141 | 142 | 157 |
| Capex | (28) | (38) | (42) | (34) | (52) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 |
| Profit before tax | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 |
| Net profit | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 |
| EPS (₹) | 2.94 | 3.36 | 2.37 | 3.57 | 3.87 | 3.80 | 3.84 | 3.31 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| ANTHEM BIOSCIENCES LTD | 52,995 | 136.9 | 17.42 | 54.7 | 19.5 | 26.6 | — | 42.0 |
| ADVANCED ENZYME TECH LTD ◆ | 3,286 | 19.8 | 1.95 | 11.6 | 10.3 | 13.4 | 8.2 | 33.7 |
| CCME GLOBAL LIMITED | 136 | 60.0 | 3.39 | — | (1.8) | (1.8) | — | — |
| VIVO BIO TECH LTD. | 39 | 4.1 | 0.41 | 4.9 | (1.8) | 3.2 | 0.6 | 31.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Advanced Enzymes buyback daily report - no shares bought back on Sep 11, 2026 | corporate actions | medium | — | — |
| 10 Sept 2026 · Daily buyback report: 45,410 shares bought back on Sept 10, 2026 | corporate actions | high | — | — |
| 10 Sept 2026 · Special window for physical share dematerialization | compliance | minimal | — | — |
| 9 Sept 2026 · Advanced Enzymes buys back 46,212 shares at avg Rs 299.54 on Sept 9 | corporate actions | low | — | — |
| 8 Sept 2026 · ADVANCED ENZYME TECH buys back 36,543 shares at avg Rs 299.50 on Sept 8, 2026 | corporate actions | medium | — | — |
| 8 Sept 2026 · Advanced Enzyme Technologies extinguishes 8.25 lakh shares from buyback | corporate actions | high | — | — |
| 7 Sept 2026 · Advanced Enzyme Tech buys back 31,197 shares at avg Rs 295.91 on Sept 7, 2026 | corporate actions | low | — | — |
| 5 Sept 2026 · Five Promoter Group members seek reclassification to Public category | ownership changes | medium | — | — |
| 4 Sept 2026 · Advanced Enzyme Tech buys back 55,332 shares at avg Rs 297.93 | corporate actions | high | — | — |
| 3 Sept 2026 · Advanced Enzyme Tech buys back 31,571 shares at avg price Rs 295.39 | corporate actions | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| Shree Ganesh Biotech (India) L |
| 20 |
| 24.5 |
| 0.31 |
| — |
| 0.6 |
| 0.8 |
| — |
| (7.0) |
| GENOMIC VALLEY BIOTECH LIMITED | 10 | 262.5 | 2.45 | — | 0.8 | 1.0 | — | 40.5 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 19.8 | 28.9 | 58 of 175 | 67% |
| P/B | 1.9 | 3.3 | 51 of 169 | 70% |
| ROCE | 13.4 | 10.7 | 77 of 189 | 60% |
| ROE | 10.3 | 9.9 | 88 of 177 | 51% |
| Debt / Equity | 0.0 | 0.1 | 55 of 177 | 69% |
| EBITDA margin | 33.7 | 17.7 | 24 of 170 | 86% |
| Revenue growth | 2.1 | 15.3 | 123 of 166 | 26% |
| Profit growth | (4.6) | 30.0 | 110 of 164 | 33% |
| Market cap | 3286 | 803 | 70 of 188 | 63% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
